Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
CHLA is engaging with internal and external partners to develop healthcare solutions that deliver lifelong benefits for conditions that originate in childhood.
Point of care testing (POCT) enables rapid diagnostic tests to be performed while a patient is at a PoC facility, without the need for complex equipment or a wait of hours to days for reports from outside labs.
The Universidad Nacional Autónoma de México’s technology transfer office—Coordinación de Innovación y Desarrollo—provides a one-stop shop for innovation emerging from Mexico.
Since 2006, BioWin, the health cluster of the Belgian region of Wallonia, has powered a renaissance of technological and scientific excellence in cell therapy and regenerative medicine.
Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA.
Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development.
The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.
Histide’s Cell Recoding Molecules provide a diverse source of nonmutagenic extracellular therapeutic agents for tissue regeneration and disease healing.
Probiodrug’s novel approach targets a modified form of β-amyloid, which has a key role in the creation of toxic Aβ oligomers. The company’s lead product is a first-in-class oral small-molecule glutaminyl cyclase inhibitor.
Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing.
Today, academic-industrial partnerships are part of an integrated development strategy for any of the world’s top ten pharmaceutical companies and a growing number of academic institutions.
Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.
Next-generation sequencing platforms are building market share not only in the research setting but also increasingly in population research and clinical applications.
Venture capital investment in devices remains lackluster, but megamergers and startups in digital health, drug delivery and minimally invasive technology are providing new impetus to today’s evolving medical technology industry.
After a period of setbacks and the exodus of high-profile companies from neuroscience research and development, industry leaders predict a rebound in neuroscience investment and deal activity in areas such as pain.